Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | FPI-2265 |
Synonyms | |
Therapy Description |
FPI-2265 is a radioconjugate comprising the radionuclide actinium-225 linked to a monoclonal antibody that targets PSMA, which delivers radiation to PSMA-expressing tumor cells, potentially resulting in antitumor activity (Cancer Res (2024) 84 (7_Supplement): CT224). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
FPI-2265 | FPI 2265|FPI2265|225Ac-PSMA-I&T | FPI-2265 is a radioconjugate comprising the radionuclide actinium-225 linked to a monoclonal antibody that targets PSMA, which delivers radiation to PSMA-expressing tumor cells, potentially resulting in antitumor activity (Cancer Res (2024) 84 (7_Supplement): CT224). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT05219500 | Phase II | FPI-2265 | Targeted Alpha Therapy With 225Actinium-Prostate Specific Membrane Antigen (PSMA)-I&T of Castration-resISTant Prostate Cancer (TATCIST). (TATCIST) | Recruiting | USA | 0 |
NCT06402331 | Phase II | FPI-2265 | FPI-2265 (225Ac-PSMA-I&T) for Patients With PSMA-Positive Metastatic Castration-Resistant Prostate Cancer (mCRPC) (AlphaBreak) | Recruiting | USA | 0 |